REGN Q2 2023 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.2B+10.5% YoY

Gross Profit

$2.7B83.9% margin

Operating Income

$1.0B32.2% margin

Net Income

$968M30.7% margin

EPS (Diluted)

$8.50

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

$1.0B

Free Cash Flow

$909M

Stock-Based Comp.

$202M

Balance Sheet

Total Assets

$30.7B

Total Liabilities

$6.6B

Stockholders' Equity

$24.0B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.2B	$2.9B	+10.5%
Gross Profit	$2.7B	$2.5B	+6.6%
Operating Income	$1.0B	$1.3B	-22.2%
Net Income	$968M	$852M	+13.6%

Revenue Segments

Product

$1.8B56%

Collaboration Revenue

$1.3B42%

Product and Service, Other

$69M2%